Alligator Bioscience AB has appointed Søren Bregenholt as chief executive, effective 1 June, to lead the Swedish company’s international expansion and business development activities. Malin Carlsson, currently chief operating officer, will be interim CEO until Dr Bregenholt takes up his new position.
Dr Bregenholt, who holds a PhD from the University of Copenhagen and did post-doctoral training at Institut Pasteur in France, has worked for more than 20 years in the global pharma and biotech industries. Most recently, he was CEO at Macrophage Pharma Ltd in the UK. Before that, he was an executive at both Novo Nordisk A/S and Symphogen A/S in Denmark.
Alligator Bioscience announced the appointment on 18 March 2021.
Copyright 2021 Evernow Publishing Ltd